#### MEDICAID DRUG REBATE PROGRAM

Release Number 61

\* \* \* IMMEDIATE ATTENTION REQUIRED \* \* \*

NOTE TO: All State Medicaid Directors

#### BANKRUPTCY FILINGS BY DRUG LABELERS

Region VI received notification that Vangard Labs, (Labeler Code 00615), and Syosset Laboratories, Inc. (Labeler Code 47854), filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code, in the Bankruptcy Court. It is important that States protect their interest (and the Federal Government's interest) in the rebates that are owed.

States are expected to file a proof of claim for their drug rebates in any bankruptcy proceeding of a drug manufacturer from whom a drug rebate is owed. Generally, a State would have six months under Chapter 11 USC 502(b)(9) to file a proof of claim for pre-petition obligations from the date the petition for bankruptcy is filed. Attorneys representing State Agencies should be able to protect their interest in such matters, once the State's obligation to file a claim is made clear. The post-petition rebate claims could also be affected by the bankruptcy proceedings. Therefore, States should take steps to assure such rebates are properly pursued.

## ALSCRIPS

A repackager named ALSCRIPS (Labeler Code 54569), apparently does not wish to be an active participant in the rebate program. They do, however want their products covered by Medicaid. ALSCRIPS has included their NDC number AND the NDC number from the company they purchased products from on the package. They are telling physicians to bill Medicaid using the "other" NDC number. Drug products marketed by the ALSCRIPS company using the ALSCRIPS label are not eligible for Federal financial participation (FFP), and State pharmacies should be alerted to this illegal practice.

We have notified both the Food and Drug Administration and the Office of the Inspector General, and requested that they investigate this matter.

## HCFA HOME PAGE ON THE INTERNET

Effective July 12, the following drug rebate data are available from the HCFA home page via INTERNET at http://www.hcfa.gov: all memoranda to State Medicaid Directors, all memoranda to participating drug labelers, the Consumer Price Index - Urban (CPI-U) values, the 91-day Treasury bill (T-bill) rates to two decimal positions, all State drug utilization for 1991 - 1995, all drug product baseline data (except for prices), drug labeler contact information for all participating drug companies, and a copy of the national drug rebate agreement.

Within 30 days, we plan to add the interest calculation methodology, the formula for calculating unit rebate amounts, a current listing of drugs subject to the federal upper limit (FUL), and the current quarterly listing of less-than-effective (LTE)/identical, related or similar (IRS) drugs as determined by the Food and Drug Administration. Comments and suggestions on the home page should be referred to Al Beachley at (410) 786-3276 or abeachley@hcfa.gov.

## STATE REPORTING OF UNMATCHED NDC NUMBERS WITH HCFA DATA BASE

It has come to our attention that there are still manufacturers' NDC numbers that have not been reported to HCFA. The National Rebate Agreement requires manufacturers to report all their NDC numbers to HCFA. One State has reported unmatched NDC(s) on their State tape for Ortho (Labeler Code 59676). Ortho has been contacted and will be sending HCFA their unreported NDC(s). Any unmatched NDC numbers from Johnson & Johnson (Ortho, McNeil, OrthoBioTech & Janssen) or any other participating manufacturer should first be reported to the company involved to ascertain that this is a valid NDC number for the company. If the number is valid, HCFA should be alerted so that contact can be made with the company to get the information. HCFA should be contacted if further assistance is needed.

## DRUG CATEGORY CHANGE

A situation regarding Drug category changes has caused us to change the way we recalculate prior quarter URAs for one specific situation only. If a repackager using their own NDC on a repackaged product begins buying from a company that will cause the Drug Category to change from or to "N", URAs back to the start of the product history will NOT be recalculated and will NOT cause PPA records to be generated. The Unit Rebates will only be recalculated for those quarters (if necessary), subsequent to the change in purchasing company. If you have any questions, please call Vince Powell on (410) 786-3314.

## USING UPPS FIELD FOR CALCULATING UTILIZATION

We have, again, received a call from a drug company complaining that some States are NOT using their Units Per Package Size (UPPS) field when calculating total utilization for unbreakable packages. These States instead are using the UPPS (or its equivalent field) from the Medispan or First Databank file. Please remember that when calculating utilization for unbreakable packages, multiply the number of scripts times the UPPS field FROM THE HCFA TAPE to determine total utilization. DO NOT use this information from any other source. The HCFA file has the Units defined by the drug company which correspond to the way the company calculates units in order to develop their Average Manufacturer's Price (AMP). Regardless of whether the other files contain a UPPS field that matches NCPDP standards on rounding or unit values that are used for developing AWP, etc., the only accurate fields FOR THE DRUG REBATE PROGRAM FILES are those sent by HCFA.

#### NEW LABELER

The following labeler has entered into a drug rebate agreement and will join the rebate program on October 1, 1996:

P.L. Development, Inc. (Labeler Code 59726).

## LABELER TERMINATIONS

The following labelers are being terminated effective October 1, 1996 for failure to submit pricing data:

ConvaTec (Labeler Code 00519),

Beiersdorf, Incorporated (Labeler Code 10356),

Ion Laboratories, Incorporated (Labeler Code 55532),

Dawn Pharmaceuticals (Labeler Code 58865),

CooperVision Pharmaceuticals, Incorporated (Labeler Code 59426), and

Amkas Laboratories, Incorporated (Labeler Code 61073).

Colorplast Corporation (Labeler Code 62123) has withdrawn their Drug Rebate Agreement. Since they only manufacture medical devices, they were not eligible to participate in the program.

Page 4 - Medicaid Drug Rebate Program Release Number 61

Delmont Laboratories, Incorporated (Labeler Code 48532) and Pharmed Group (Labeler Code 54252) have requested to be terminated from the program effective October 1, 1996.

## ATTACHMENTS

Copies of the topic index and the latest listing of the 90-day treasury bill auction rates for the period of September 5, 1995 through July 22, 1996 are attached.

Please remember to direct your drug rebate questions to a staff member on the listing we provided with release number 53.

Sally K. Richardson Director Medicaid Bureau

## 2 Attachments

cc:

All State Technical Contacts

All Regional Administrators

All Associate Regional Administrators, Division of Medicaid

# TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 61

A Drug Listing	TOPIC	RELEASE #
Adjustment Code for Forms HCFA-304 & HCFA-304a   57   Bankruptcy - Drug Labelers   19-61   Best Price to DSH Covered Entities   36   Betaseron - Coverage & Reimbursement   38-40   Bulk Transfer/Buy-Out of Major Pharm. Assets   54-55   Caverject Coverage   55   Closure During Federal Furloughs   57   Confidential Information Release   17   Constant Disputes by Drug Labelers   23   CPIU Information   09   Dataset Name Changes on Quarterly Rebate Tapes   41   Dipyridamole Issue   26   Dispute Resolution   19   15   S5   Process Stages   45   Morkgroup Survey Results   42   Dispute Settlements   59   Drug Category Change   61   Change Effective Date   23   Change Effective Date   24   Change Effective Date   26   Change Effective Date   27   Change Effective Date   28   Change Effective Date   29   Change Effective Date Revisions   23   24   Dispute Products   25   Change Effective Date Revisions   26   Change Effective Date Revisions   27   24   Dispute Products   27   27   27   27   27   27   27   2		
Bankruptcy - Drug Labelers         19-61           Best Price to DSH Covered Entities         36           Betaseron - Coverage & Reimbursement         38-40           Bulk Transfer/Buy-Out of Major Pharm. Assets         54-55           Caverject Coverage         55           Closure During Federal Furloughs         57           Confidential Information Release         17           Constant Disputes by Drug Labelers         23           CPIU Information         09           Dataset Name Changes on Quarterly Rebate Tapes         41           Dispute Resolution         19           Issues         55           Process Stages         45           Workgroup Survey Results         19           Drug Estilements         59           Drug Edegory Change         61           Drug Efficacy Study & Implementation (DESI)         61           Change Effective Date         20           Change Effective Date         20           Change Schedule         18           Effective Date Revisions         19           Experimental Drugs - Coverage         30           Enteral Nutritional Products - Coverage         30           Experimental Drugs - Coverage         31           Informatio	<del>-</del>	= -
Best Price to DSH Covered Entities Betaseron - Coverage & Reimbursement 38-40 Bulk Transfer/Buy-Out of Major Pharm. Assets Caverject Coverage 55 Closure During Federal Furloughs 57 Confidential Information Release 17 Constant Disputes by Drug Labelers 23 CPIU Information 99 Dataset Name Changes on Quarterly Rebate Tapes 41 Dipyridamole Issue 26 Dispute Resolution 99 Definition 19 Issues 55 Process Stages 45 Workgroup Survey Results 55 Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) 61 Change Effective Date 61 Drug Efficacy Study & Implementation (DESI) 62 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 43 Hotline 199 Experimental Drugs - Coverage 43 Hotline 53 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 11 Invoices 67 Correct Labeler Address 67 Format 67 Incomplete Drug Labeler Data 68 Incorrect Invoicing 68 Remittance Advice Report Survey 68 Submission 69 Submitting for Multiple Quarters 68 Submitting for Multiple Quarters 68 Submitting to Drug Labelers 67 Submitting to Drug Labelers 67 Late Submission 69 Late Submission 69 Magnetic Media 79 New Address for Shipping (Effective 6/1/95) 52 Rejections 615-23	<del>-</del>	
Betaseron - Coverage & Reimbursement		
Bulk Transfer/Buy-Out of Major Pharm. Assets Caverject Coverage Closure During Federal Furloughs Confidential Information Release 17 Constant Disputes by Drug Labelers 23 CPIU Information 09 Dataset Name Changes on Quarterly Rebate Tapes 41 Dipyridamole Issue Dispute Resolution Definition 19 Issues Process Stages Workgroup Survey Results Dispute Settlements Drug Efficacy Study & Implementation (DESI) Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation Enteral Nutritional Products - Coverage Enteral Nutritional Products - Coverage Enteral Products Experimental Drugs - Coverage Hotline Information Sharing Interest Calculation under Section V(b) 19 Internet Home Page Invoices Correct Labeler Address Format Incomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission Submitting for Multiple Quarters Submistion of Quarterly Prices Labeler Contact File Changes Late Submission of Quarterly Prices Late Submission of Quarterly Prices Rejections New Address for Shipping (Effective 6/1/95) Rejections Shipments 15-23		
Caverject Coverage Closure During Federal Furloughs Confidential Information Release Constant Disputes by Drug Labelers Constant Disputes by Drug Labelers CPIU Information Definition Dispute Resolution Definition Issues Process Stages Process Stages Process Stages Process Stages Process Study & Implementation (DESI) Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation Experimental Drugs - Coverage Hotline Information Sharing Interest Calculation under Section V(b) Internet Home Page Incomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission Submitting to Prug Labelers Labeler Contact File Changes Late Submission of Quarterly Prices Shipments New Address for Shipping (Effective 6/1/95) Rejections Ney Address for Shipping (Effective 6/1/95) Rejections Shipments 15-23		
Closure During Federal Furloughs Confidential Information Release Constant Disputes by Drug Labelers Constant Disputes by Drug Labelers CPIU Information O9 Dataset Name Changes on Quarterly Rebate Tapes Dispute Resolution Definition Issues Process Stages Workgroup Survey Results Drug Category Change Change Effective Date Change Effective Date Change Schedule Effective Date Revisions Experimental Drugs - Coverage Hotline Index for Drug Rebate Notes Information Sharing Interest Calculation under Section V(b) Interest Calculation under Section V(b) Interest Calculation under Section V(b) Submission Submitting for Multiple Quarters Submistion of Quarterly Prices Labeler Contact File Changes Magnetic Media New Address for Shipping (Effective 6/1/95) Rejections Neight Address Rejections Nipper Address Rejections Magnetic Media New Address for Shipping (Effective 6/1/95) Rejections Shipments 15-23		
Constidential Information Release 17 Constant Disputes by Drug Labelers 23 CPIU Information 99 Dataset Name Changes on Quarterly Rebate Tapes 41 Dipyridamole Issue 26 Dispute Resolution 91		
Constant Disputes by Drug Labelers 23 CPIU Information 09 Dataset Name Changes on Quarterly Rebate Tapes 41 Dipyridamole Issue 26 Dispute Resolution 19 Issues 55 Process Stages 45 Workgroup Survey Results 42 Dispute Settlements 59 Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) 20 Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 63 Correct Labeler Address 65 Format 70 Incomplete Drug Labeler Data 71 Incomplete Drug Labeler Data 72 Incomplete Drug Labeler Data 73 Submission 74 Submisting for Multiple Quarters 75 Submission 79 Submitting for Multiple Quarters 75 Labeler Contact File Changes 75 Late Submission 67 Late Submission 67 Development 75 Late Submission 75 Late		_
CPIU Information Dataset Name Changes on Quarterly Rebate Tapes 41 Dipyridamole Issue 26 Dispute Resolution  Definition 19 Issues 55 Process Stages 45 Workgroup Survey Results 42 Dispute Settlements 59 Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 1 Invoices 61 Correct Labeler Address 63 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remitance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes Late Submission of Quarterly Prices 33 LTE/IRS Drugs Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 51 Shipments 15-23		
Dataset Name Changes on Quarterly Rebate Tapes 26 Dispute Resolution  Definition 19 Issues 55 Process Stages 45 Workgroup Survey Results 59 Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 11 Invoices 61 Correct Labeler Address 65 Format 15 Incomplete Drug Labeler Data 18 Incorrect Invoicing 85 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 515-23		_
Dispridamole Issue Dispute Resolution  Definition Issues Process Stages Process Stages Process Stages Workgroup Survey Results Dispute Settlements Drug Category Change Change Effective Date Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation Enteral Nutritional Products - Coverage Submitting for Multiple Quarters Format Incorrect Invoicing Remitted Nature Report Survey Submission Submitting for Multiple Quarters Submitting to Drug Labelers Late Submission of Quarterly Prices Magnetic Media New Address for Shipping (Effective 6/1/95) Experimental Media New Address for Shipping (Effective 6/1/95) Experiment Media New Address for Shipping (Effective 6/1/95) Experiment Media New Address for Shipping (Effective 6/1/95) Experiment Media New Address for Shipping (Effective 6/1/95) Experiments Stages Stag		
Dispute Resolution  Definition Issues Frocess Stages Workgroup Survey Results Dispute Settlements Drug Category Change Change Stedie Effective Date Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation Experimental Drugs - Coverage Hotline Difformation Sharing Information Sharing Interest Calculation under Section V(b) Dinternet Home Page Invoices  Correct Labeler Address Format Incorrect Invoicing Remittance Advice Report Survey Submission Submitting for Multiple Quarters Submitting to Drug Labelers Labeler Contact File Changes Late Submission of Quarterly Prices Magnetic Media New Address for Shipping (Effective 6/1/95) Rejections Shipments  15-23		
Definition Issues Process Stages Process Stages Workgroup Survey Results Dispute Settlements Drug Efficacy Change Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products Experimental Drugs - Coverage Hotline Information Sharing Interest Calculation under Section V(b) Internet Home Page Invoices Correct Labeler Address Format Incomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission Submitting for Multiple Quarters Submitting to Drug Labelers Labeler Contact File Changes Late Submission of Quarterly Prices Magnetic Media New Address for Shipping (Effective 6/1/95) Rejections Shipments 15-23		20
Issues Process Stages 45 Process Stages 45 Workgroup Survey Results 59 Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 61 Correct Labeler Address 65 Format 70 Incomplete Drug Labeler Data 71 Incorrect Invoicing 72 Remittance Advice Report Survey 73 Submission 74 Submitting for Multiple Quarters 74 Submitting to Drug Labelers 75 Labeler Contact File Changes 75 Magnetic Media 76 New Address for Shipping (Effective 6/1/95) 52 Rejections 75 Shipments 15-23	<del>-</del>	1.0
Process Stages Workgroup Survey Results Dispute Settlements Drug Category Change Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation Enteral Nutritional Products - Coverage Experimental Drugs - Coverage Hotline Index for Drug Rebate Notes Information Sharing Interest Calculation under Section V(b) Internet Home Page Invoices Correct Labeler Address Format Incomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission Submisting to Drug Labelers Submitting to Drug Labelers Labeler Contact File Changes Late Submission of Quarterly Prices Magnetic Media New Address for Shipping (Effective 6/1/95) Schipments Shipments 15-23		
Workgroup Survey Results 59 Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 61 Incomplete Drug Labeler Data 18 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission 6 Quarterly Prices 33 LTE/IRS Drugs 36 Magnetic Media 86 New Address for Shipping (Effective 6/1/95) 52 Rejections 515-23		
Dispute Settlements Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24 Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 53 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 61 Incorrect Labeler Address 65 Format 70 Incorrect Invoicing 71 Remittance Advice Report Survey 71 Submission 72 Submission 73 Submitting for Multiple Quarters 73 Submitting to Drug Labelers 74 Labeler Contact File Changes 75 Late Submission 67 Magnetic Media 76 New Address for Shipping (Effective 6/1/95) 52 Rejections 71 Remittance Advice Report Survey 61 Rejections 75 Re		_
Drug Category Change 61 Drug Efficacy Study & Implementation (DESI) Change Effective Date 20 Change Schedule 18 Effective Date Revisions 23-24  Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Correct Labeler Address 56 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 32 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		
Drug Efficacy Study & Implementation (DESI) Change Effective Date Change Schedule Effective Date Revisions Duplicate Discount/Rebate Mechanism Implementation Enteral Nutritional Products - Coverage Experimental Drugs - Coverage Hotline Index for Drug Rebate Notes Information Sharing Interest Calculation under Section V(b) Internet Home Page Invoices Correct Labeler Address Format Incomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission Submitting for Multiple Quarters Submitting to Drug Labelers Labeler Contact File Changes Late Submission of Quarterly Prices Magnetic Media New Address for Shipping (Effective 6/1/95) Rejections Shipments 15-23		39
Change Effective Date Change Schedule Effective Date Revisions  Enteral Products Enteral Products Experimental Drugs - Coverage Enteration Staring Information Sharing Interest Calculation under Section V(b) Internet Home Page Incomplete Drug Labeler Data Incomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission Submitting for Multiple Quarters Submitting to Drug Labelers Late Submission of Quarterly Prices Late Submission of Quarterly Prices Magnetic Media New Address for Shipping (Effective 6/1/95) Rejections Shipments  138 23-24 23-24 24 23-24 24 23-24 24 24 24 24 24 24 24 24 24 24 24 24 2	15 111151 1 1 1 5	
Change Schedule Effective Date Revisions 23-24  Duplicate Discount/Rebate Mechanism Implementation 33  Enteral Nutritional Products - Coverage 30  Enteral Products 19  Experimental Drugs - Coverage 43  Hotline 53  Index for Drug Rebate Notes 31  Information Sharing Interest Calculation under Section V(b) 29  Internet Home Page Invoices  Correct Labeler Address Format 1ncomplete Drug Labeler Data Incorrect Invoicing Remittance Advice Report Survey Submission 19  Submitting for Multiple Quarters Submitting to Drug Labelers  Labeler Contact File Changes Late Submission of Quarterly Prices 15  Magnetic Media New Address for Shipping (Effective 6/1/95) Separate Submission 15  Rejections Shipments 15-23		20
Effective Date Revisions  Duplicate Discount/Rebate Mechanism Implementation  Enteral Nutritional Products - Coverage  30  Enteral Products  Experimental Drugs - Coverage  43  Hotline  Salindex for Drug Rebate Notes  Information Sharing  Interest Calculation under Section V(b)  Internet Home Page  Correct Labeler Address  Format  Incomplete Drug Labeler Data  Incorrect Invoicing  Remittance Advice Report Survey  Submission  Submitting for Multiple Quarters  Submitting to Drug Labelers  Labeler Contact File Changes  Late Submission of Quarterly Prices  Magnetic Media  New Address for Shipping (Effective 6/1/95)  Rejections Shipments  30  23-24  24  25-24  26  27  28  28  29  29  20  20  20  21  21  22  23  24  25  26  27  28  28  28  29  20  20  20  20  20  20  20  20  20	_	
Duplicate Discount/Rebate Mechanism Implementation 33 Enteral Nutritional Products - Coverage 30 Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	_	_
Enteral Nutritional Products - Coverage 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		_
Enteral Products 19 Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 61 Invoices 66 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		
Experimental Drugs - Coverage 43 Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Correct Labeler Address 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	_	
Hotline 53 Index for Drug Rebate Notes 31 Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Correct Labeler Address 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 55ipments 15-23		
Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Correct Labeler Address 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		_
Information Sharing 57 Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices 36 Correct Labeler Address 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Index for Drug Rebate Notes	31
Interest Calculation under Section V(b) 29 Internet Home Page 61 Invoices  Correct Labeler Address 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		57
Internet Home Page 61 Invoices 36 Correct Labeler Address 36 Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		29
Correct Labeler Address Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 22 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 82 Rejections 15 Shipments		61
Format 03 Incomplete Drug Labeler Data 18 Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Invoices	
Incomplete Drug Labeler Data Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) Sejections 15 Shipments	Correct Labeler Address	36
Incorrect Invoicing 26 Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Format	03
Remittance Advice Report Survey 35 Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Incomplete Drug Labeler Data	18
Submission 19 Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Incorrect Invoicing	26
Submitting for Multiple Quarters 36 Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Remittance Advice Report Survey	35
Submitting to Drug Labelers 28 Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Submission	19
Labeler Contact File Changes 32 Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Submitting for Multiple Quarters	36
Late Submission of Quarterly Prices 33 LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		28
LTE/IRS Drugs 26 Magnetic Media New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23	Labeler Contact File Changes	32
Magnetic Media  New Address for Shipping (Effective 6/1/95) 52  Rejections 15  Shipments 15-23	Late Submission of Quarterly Prices	33
New Address for Shipping (Effective 6/1/95) 52 Rejections 15 Shipments 15-23		26
Rejections 15 Shipments 15-23		
Shipments 15-23		_
-		_
Specification Revision 14		
	Specification Revision	14

TOPIC RELEASE #

Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
Medical Supplies & Devices	03-16-26
Metric Conversion/Rounding	18
New Drug Products	41
New Rebate Agreement Status	23
OBRA '93	40
Overpayments Due to AMP Recalculations	57
PHS Drug Pricing Program	44
Prior Period Adjustments (PPAs)	60
Prior Period Adjustments - Eli Lilly & Company	37
Prior Authorization	55
Prior Period Adjustments	14-16
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Labeler Contact File	26
Quarterly Reporting - Form HCFA-64, 9r	40
Quarterly Tape Submission to HCFA	60
Quarterly Update File	14
Rebates	
Calculation Formula	07
Less than Administrative Costs	40
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
Rejection of State Records Matching LTE Drugs	41
	-52-53-56
Reporting Utilization Changes to Labelers	57
Rescission of Termination for Novopharm USA	39
Separate Rebate Agreements with Manufacturers	38
Special Advisory Group	16
Staff Listing	53
Staff Relocation	52
Standard Summary Record Format	13
State Application of the FUL Program	48
State Contact Information	23-26-41
State Coverage	
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Plan Amendment Requirement	47
State Responsibility - Terminated Drugs	19
State Utilization Data Records - Corrections	51
State Utilization Data Study (SUDS)	33
State Utilization Tape Submission Procedures	58
Tape/Cartridge Return Policy	19
Tape Submission Checklist	30
Terminated/Deleted Records	44

TOPIC	ELEASE #
Timely Receipt of Tapes/Notices of Mailing Tolerance Threshold Clarification	45
For Interest	48
Rebate Amount Adjustments	44
Unit-Dose Packaging	15
Unit Per Package Size	03
Unit Rebate Amount (URA)	
Edits	43
Erroneous Amounts	51
Invoice when the Amount is Zero	44
Unit Type	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Data	
Corrections/Problems	18
Late Submission	18
Receipt	29-31
Record Format	08-13
Set Naming Requirements	19
Tapes	40
Transmitting Corrections/Adjustments to HCFA	16-40
Vaccine	
Deletions	26
Exclusions	19-23
Policy Clarification	25

(Revised 24 July 1996)

## WEEKLY U.S. T-BILL DISCOUNT RATE

The latest weekly 90-day treasury bill auction rates for September 5, 1995 through July 22, 1996 are:

DATE OF AUCTION		TRUE DISCOUNT RATE
09/05/95		5.463
09/12/95		5.504
09/19/95		5.409
09/25/95		5.293
10/02/95		5.504
10/10/95		5.471
10/16/95		5.483
10/23/95		5.376
10/30/95		5.450
11/06/95		5.525
11/13/95	5.599	
11/20/95	5.503	
11/27/95	5.483	
12/04/95	5.450	
12/11/95	5.463	
12/18/95	5.306	
12/26/95	5.054	
01/02/96	5.190	
01/09/96	5.178	
01/16/96	5.170	
01/22/96	5.137	
01/29/96	5.157	
02/05/96	5.025	
02/12/96	4.939	
02/20/96	4.918	
02/26/96	4.987	
03/04/96	5.020	
03/11/96	5.081	
03/18/96	5.155	
03/25/96	5.123	
04/01/96	5.209	
04/08/96	5.164	
04/15/96	4.999	
04/22/96	5.102	
04/30/96	5.135	
05/06/96	5.155	
05/13/96	5.155	
05/20/96	5.164	
05/28/96	5.164	
06/03/96	5.229	
06/10/96	5.299	
06/17/96	5.217	
06/24/96	5.238	
07/01/96	5.258	
07/08/96	5.353	
07/15/96	5.332	
07/22/96	5.279	

FAB134:Dmccarthy, 62079.

State61.WP